OC
KALA icon

Oppenheimer & Co’s KALA BIO KALA Stock Holding History

Oppenheimer & Co’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25
Closed -$13K – 1395
2022
Q3 		$13K Hold
25
– – ﹤0.01% 1351
2022
Q2 		$18K Buy
25
+13
+108% +$20.4K ﹤0.01% 1389
2022
Q1 		$40K Buy
12
+1
+9% +$2.62K ﹤0.01% 1447
2021
Q4 		$34K Sell
11
-5
-31% -$23.2K ﹤0.01% 1475
2021
Q3 		$107K Buy
16
+4
+33% +$34.5K ﹤0.01% 1447
2021
Q2 		$163K Buy
+12
New +$189K ﹤0.01% 1442

Other funds holding KALA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oppenheimer & Co's KALA Position: Q4 2022 in Review

Oppenheimer & Co sold out of KALA BIO (KALA) in Q4 2022, closing a stake of 25 shares — an estimated $13K sold.

Oppenheimer & Co first reported a position in KALA in Q2 2021 and held it in 6 quarters. The position peaked at $163K in Q2 2021. 28 funds tracked by Wall St. Rank hold KALA as of Q4 2022.

  • Oppenheimer & Co reported no remaining KALA BIO position as of Q4 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 25 KALA BIO shares in Q4 2022, an estimated $13K.
  • Oppenheimer & Co first reported a position in KALA BIO in Q2 2021 and held it in 6 quarters.
  • Oppenheimer & Co's KALA BIO position peaked at $163K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held KALA BIO as of Q4 2022.

Based on Oppenheimer & Co's 13F filing for Q4 2022, filed 8 Feb 2023.